FTCD

Across TCGA pan-cancer cohorts, FTCD mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FTCD data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FTCD mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FTCD expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC and LUAD are the cancer types where FTCD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.838	0.268	.002	59	view →
LUAD	DFS	Median	All	0.711	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FTCD–CCRCC (OS)

Open the CCRCC breakdown →